Capital Planning Valuation Strategy™
© 2024 CPVS™
Medical Funding Professionals is a registered investment advisor located in Nevada. Medical Funding Professionals and its representatives are in compliance with the current filing requirements imposed upon registered investment advisors by those jurisdictions in which Medical Funding Professionals maintains clients. Medical Funding Professionals may only transact business in those states in which it is registered or qualifies for an exemption or exclusion from registration requirements. Medical Funding Professionals’ web site is limited to the dissemination of general information pertaining to its advisory services. Accordingly, the publication of Medical Funding Professionals’ web site on the Internet should not be construed by any consumer and/or prospective client as either legal advice or Medical Funding Professionals’ solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation.
Biotech and Medical Device Companies Raise $913M in a 5-IPO Week
It was almost a billion-dollar week for life sciences IPOs last week, following a Q1 for IPOs overall that we haven’t seen since the tech bubble in 2000. The acceleration of biotech and medtech research, combined with the eagerness of the market indicate no signs of that slowing any time soon.
But there are thousands of promising companies that need funding and aren’t yet ready for an IPO. The democratization of the capital markets opens up other possibilities for these companies than the traditional angel/VC path. For example, Regulation A+ allows companies to raise up to $75M every 12 months at a lower cost (and much lower regulatory burden) than an IPO—a great option for companies needing substantial capital to finish their research, conduct clinical trials, or go to market.
Biotech and medical device companies raise $913M in a five-IPO week – MedCity News
The five life sciences IPOs this week continues the steady march companies are making to the public markets this year. This week’s activity follows a first quarter that Renaissance Capital calculates was the busiest for newly public companies since 2000.